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A b s t r A c t
Vitamin B12 or cobalamin deficiency is a common problem in adult patients, which 
is however frequently missed. The most common cause of cobalamin deficiency is 
the food cobalamin malabsorption syndrome (>60% of all cases). Neuropsychiatric 
manifestations can be the presenting and only early sign of cobalamin deficiency even 
in the absence of hematologic abnormalities. The deficiency can occur despite serum 
cobalamin levels at low normal values; thus, normal vitamin B12 levels have been re-
vised upward to >350 pg/ml. Early detection and treatment are important to prevent 
structural and irreversible damage. The causes and ailments of vitamin B12 deficiency 
are herein overviewed and a diagnostic and therapeutic strategy is outlined.
I N t r O D U c t I O N
Vitamin B12 or cobalamin, a water-soluble vitamin, is vital for cell division, DNA 
synthesis, erythropoiesis, and normal function of the nervous system via the formation 
of myelin sheaths and the synthesis of neurotransmitters.1-8 The human body does not 
manufacture this vitamin and gets it supplied from animal products or fortified cere-
als. It is produced by anaerobic bacteria and is found in foods of animal origin (e.g., 
meat, fish, dairy products, and eggs). On its way into the cell, vitamin B12 is absorbed by 
lysosomes and enters the cell with the aid of the transport protein CblF. It appears that 
a second transport protein, ABCD4, is also necessary for this step. Both proteins may 
be a cause of hereditary vitamin B12 deficiency.9-11 In combination with folate, vitamin 
B12 is an essential cofactor in the metabolism of homocysteine and methylmalonic acid 
(MMA); when vitamin B12 is truly deficient, the levels of these two metabolites rise. 
Cobalamin is a cofactor and coenzyme in many biochemical reactions, including DNA 
synthesis, methionine synthesis from homocysteine and conversion of propionyl into 
succinyl coenzyme A from methylmalonate. Methionine is required for the formation 
of S-adenosylmethionine, a universal methyl donor for about 100 different substrates, 
including DNA, RNA, hormones, proteins, and lipids.
Daily requirements of vitamin B12, recommended by the FDA and other medical 
societies, range between 2 and 5 μg (average 2.4 μg for recommended daily allow-
ance).2,4-6,8,12-16 A typical Western diet contributes 3–30 μg of cobalamin per day, while 
hepatic stores are multifold higher (>1.5 mg); cobalamin is also recycled via the en-
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terohepatic cycle, whereby it is excreted in the bile and then 
reabsorbed in the small intestine. Thus, there is a significant 
5-10-year delay between the onset of insufficient oral intake 
and the development of clinical ailments.
Dietary cobalamin is bound to animal proteins and is 
absorbed via a complex process.2,4-8 First, it is released in the 
stomach via the effect of hydrochloric acid and pepsin. Syn-
thetic vitamin B12, added to fortified foods and dietary supple-
ments, is already in free form and, thus, there is no need for 
a release process. Free cobalamin in the stomach is bound by 
glycoproteins (R-proteins) secreted from salivary glands and 
parietal cells. Intrinsic factor (IF), a weak binder of cobalamin 
in the presence of R proteins, is also released by parietal cells 
in the stomach. In the duodenum, dietary- and bile-secreted 
cobalamin-R complexes are cleaved by pancreatic enzymes, 
and free cobalamin is then bound to IF with more affinity. 
Cobalamin–IF complexes are taken up by endocytosis in the 
distal ileal mucosa. Once inside the cell, cobalamin dissoci-
ates from IF. Free cobalamin is then bound to transporter 
proteins (transcobalamins) and transported to the liver. The 
biologically-active form of the vitamin can be taken up by cells 
via endocytosis for metabolic purposes. Between 1-5% of free 
cobalamin is absorbed along the entire intestine by passive 
diffusion, which renders feasible the absorption of high doses 
(>1000 μg daily) of oral supplemental cobalamin, despite 
malabsorption disease processes.
Disruptions in the metabolic pathways of cobalamin pro-
duce elevated levels of homocysteine and methylmalonic acid 
(MMA).17 Homocysteine is neurotoxic, through overstimula-
tion of the N-methyl-D-aspartate receptors, and toxic to the 
vasculature because of activation of the coagulation system 
and adverse effects on the vascular endothelium. MMA, a 
product of methylmalonyl-CoA, can cause abnormal fatty-
acid synthesis, affecting the neuronal membrane. MMA and 
homocysteine levels are elevated before any clinical manifesta-
tions of vitamin B12 deficiency and often precede low serum 
vitamin B12 levels. Neuropsychiatric symptoms usually precede 
hematologic signs and are often the presenting manifestation 
of cobalamin deficiency.17 Diagnosing and treating vitamin B12 
deficiency is crucial since it is a reversible cause of anemia and 
demyelinating nervous system disease.
c A U s E s
The most common cause of cobalamin deficiency is the 
food-cobalamin malabsorption syndrome (>60% of all cases) 
(Table 1).1-8,12-18 Other causes comprise pernicious anemia 
(15%–20% of all cases), insufficient dietary intake, malabsorp-
tion, and rare hereditary syndromes (e.g., Imerslund-Grasbeck 
syndrome), which though appear in newborns and therefore 
do not involve adult patients. Food-cobalamin malabsorption, 
which has only recently been identified as a significant cause 
of cobalamin deficiency, particularly among the elderly, is 
characterized by the inability to release cobalamin from food 
or a deficiency of intestinal cobalamin transport proteins or 
both. Food-cobalamin malabsorption is caused primarily by 
gastric atrophy. Gastric atrophy may or may not be related to 
Helicobacter pylori infection. Other factors that may contrib-
ute to this syndrome include microbial proliferation (blind or 
stagnant loop syndrome), long-term ingestion of metformin, 
H2-receptor antagonists and proton pump inhibitors, chronic 
alcoholism, gastric surgery, partial pancreatic exocrine failure 
and Sjogren’s syndrome.5,19 A major risk factor contributing 
to vitamin B12 deficiency in developing countries is indeed a 
smoldering infection with Helicobacter pylori (Table 1).18 It is 
estimated that a 50-90% of the population is infected by H. 
pylori and this has been shown to have a direct implication in 
decreasing vitamin B12 absorption because of gastric atrophy 
observed in around 30% of individuals with H. pylori infection, 
leading to inadequate binding of vitamin B12 and intrinsic fac-
tor.7 H. pylori has been detected in up to 78% of those with 
severe vitamin B12 deficiency compared with 44% of those 
with normal levels of vitamin B12. Following treatment of H. 
pylori, 40% of patients have their vitamin B12 levels restored 
to normal within 2 years. Giardia lamblia and other intestinal 
tAblE 1. Causes of Vitamin B12 Deficiency
•	Food-cobalamin malabsorption syndrome (atrophic gastritis, 
chronic gastritis, drug interactions, small intestinal bacterial 
overgrowth)
•	Type B atrophic gastritis (associated with helicobacter pylori 
infection)
•	Lack of intrinsic factor (IF) due to immune mediated destruction 
of gastric parietal cells (pernicious anemia)
•	Nutritional deficiency (vegans, vegetarians, elderly, alcoholics, 
HIV positive, breast fed infants of vegetarian mothers)
•	Pathology of distal ileum (distal ileal resection, inflammatory 
bowel disease like Crohn’s disease, ileocaecal tuberculosis, 
Whipple’s disease, tropical sprue)
•	Surgical gastrectomy / ileal resection
•	Colonization of small bowel with bacteria or intestinal parasites 
(tapeworm)
•	Nitrous oxide inhalation (functional deficiency)
•	Drugs (metformin, antacids, proton pump inhibitors, H2 blockers, 
colchicine, phenytoin, zidovudine)
•	Increased demands (pregnancy / lactation)
•	Congenital syndrome (Imerslund-Grasbeck syndrome)
HIV = human immunodeficiency virus.
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parasites may also be responsible for chronic diarrhea and 
malabsorption, with approximately one-third of the infected 
population having decreased vitamin B12 levels.7
Pernicious anemia, or Biermer’s disease, an autoimmune 
disease, is a classical cause of cobalamin deficiency and accounts 
for 15-20% of all cases.20 It is characterized by a cell-mediated 
destruction of the fundal gastric mucosa that leads to neutral or 
slightly acidic gastric secretions despite the presence of gastrin 
(which normally increases acidity), which contain little or no 
intrinsic factor. The disease is also characterized by the presence 
of anti-intrinsic factor or antigastric parietal cell antibodies. 
Due to gastric atrophy with hypochlorhydria, patients have a 
reactive hypergastrinemia. A positive Schilling test conducted 
with use of radiolabeled vitamin B12 and combined with the 
addition of a test for anti-intrinsic factor antibodies, virtually 
confirms the diagnosis (specificity >99%); however, this test 
has dropped out of favor and is not currently available.4,8 
Pernicious anemia is associated with many other autoimmune 
disorders and with an increased frequency of gastric neoplasms, 
requiring periodic endoscopic surveillance. In contrast with the 
malabsorption syndrome, there is near absence of mucosal H. 
pylori in patients with pernicious anemia.
Low serum vitamin B12 levels compromise the immune 
response to pneumococcal vaccine because of impaired hu-
moral immunity.21 Similarly, low serum B12 levels may affect the 
results of tests like the Quantiferon Gold test for tuberculosis.
c l I N I c A l  M A N I F E s t A t I O N s
Vitamin B12 deficiency occurs in 4 stages, starting with 
declining blood levels of the vitamin (stage I), progressing 
to low cellular concentrations of the vitamin and metabolic 
abnormalities (stage II), an increased blood level of homocyst-
eine and methylmalonic acid and a decrease in DNA synthesis 
with emergence of neuropsychiatric symptoms (stage III), and 
ultimately, macrocytic anemia (stage IV).
The clinical manifestations of vitamin B12 deficiency include 
(Table 2):1-8,12-17,20,22-26
	 •	hematologic:	megaloblastic	anemia	and	pancytopenia
	 •	neurologic:	dementia;	parasthesias,	peripheral	neuropathy	
and subacute combined degeneration of the spinal cord
	 •	psychiatric:	irritability,	personality	change,	memory	impair-
ment, depression and psychosis
	 •	gastrointestinal	and	other	constitutional	symptoms:	sto-
matitis, diarrhea, constipation, loss of appetite, fatigue, 
weakness, weight loss and premature birth, and possibly
	 •	cardiovascular,	possibly	related	to	increased	homocysteine	
levels conferring increased risk of myocardial infarction 
and stroke.
Vitamin B12 crosses the placenta and is present in breast 
milk. Pregnant women with cobalamin deficiency may give 
birth to children with neural tube defects.27 Breast-fed children 
tAblE 2. Clinical Manifestations of Vitamin B12 Deficiency
Hematological Manifestations
Anemia
Pancytopenia (rare)
Neurological Manifestations
cNs manifestations
1. Dementia
2. Depression
3. Parkinson’s disease
4. Acute psychosis, reversible manic and schizophreniform 
states (Megaloblastic madness)
5. Cerebrovascular disease (homocystenemia is an independent 
risk factor for stroke)
spinal cord manifestations
1. Myelopathy (Subacute combined degeneration of spinal 
cord), ataxia, spasticity and abnormal gait
PNs manifestations
1. Neuropathy
● motor-sensory polyneuropathy (parasthesias, numbness 
and weakness)
● mononeuropathy (optic or olfactory)
● autonomic neuropathy (impotence, urinary or fecal 
incontinence
2. Myeloneuropathy (combined myelopathy and neuropathy)
cardiovascular Manifestations
Effects from anemia
Increased cardiovascular risk / angina (hyperhomocysteinemia)
Venous thromboembolic disease
GI Manifestations
Glossitis
Jaundice
Mucocutaneous ulcers (rare)
Dyspepsia (?)
Other
Vaginal mucosal atrophy
Vaginal & urinary chronic (especially fungal) infections
Hypofertility / miscarriages
Vitiligo / Hyperpigmentation
CNS = central nervous system; GI = gastrointestinal; PNS = peripheral 
nervous system
of mothers with vitamin B12 deficiency are at increased risk of 
failure to thrive, hypotonia, ataxia, and anemia.28 
Although the true prevalence of vitamin B12 deficiency is 
difficult to estimate due to varying laboratory values, meth-
ods and criteria, the Framingham Heart Study reported in 
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1994 the prevalence of vitamin B12 deficiency, as defined by 
a serum vitamin B12 level <200 pg /ml and elevated levels 
of serum homocysteine, methylmalonic acid, or both, to be 
12% among 548 elderly patients.29 According to unpublished 
data from the National Health and Nutrition Examination 
Survey, 3.2% of U.S. adults older than 50 years are estimated 
to have a serum vitamin B12 level less than 200 pg/ml.8 Other 
estimates indicate that >20% of the elderly individuals suffer 
from vitamin B12 deficiency,3 but the condition may often go 
unrecognized because the clinical manifestations are subtle. 
However, they are also potentially serious, since they may lead 
to severe, albeit reversible at early stages, neuropsychiatric 
symptomatology.17,22-26 Indeed, the non-hematologic clinical 
features of vitamin B12 deficiency can be manifest despite the 
absence of anemia.
D I A G N O s I s
Although many clinical laboratories define vitamin B12 
deficiency at a level of <150 pg / ml (<110 pmol/L; pmol/L = 
pg/ml X 0.738), or in some cases <200 pg/ml (<148 pmol/L), 
patients with values above these levels may be symptomatic 
and benefit from treatment.5,8,30 Vitamin B12 levels >350 pg/
ml (>258 pmol/L) seem to be protective against symptoms 
of vitamin B12 deficiency. Nevertheless, there is evidence that 
serum vitamin B12 concentrations might not accurately reflect 
intracellular concentrations. Furthermore, large amounts of 
folic acid can conceal the detrimental effects of vitamin B12 
deficiency by correcting the megaloblastic anemia caused by 
vitamin B12 deficiency without remedying the neurological 
damage that also develops.12 Also, high serum folate levels 
might not only mask vitamin B12 deficiency, but could also 
worsen the anemia and the cognitive symptoms produced by 
cobalamin deficiency. The ensuing delay in treatment might 
produce permanent nerve damage. Thus, in healthy individu-
als folic acid intake generally should not exceed 1 mg daily.
In patients with clinical symptoms of vitamin B12 deficiency 
and low levels of serum vitamin B12, no further confirmatory 
testing is generally needed before treatment is initiated.6 Veri-
fication with serum methylmalonic acid (MMA) and/or serum 
homocysteine level6,31,32 may be necessary in asymptomatic 
patients with high-risk conditions, symptomatic patients with 
low-normal levels of vitamin B12 (200 to 350 pg/ml), or symp-
tomatic patients in whom vitamin B12 deficiency is unlikely but 
must be excluded.8 Elevated levels of serum homocysteine and 
methylmalonic acid have been shown to be highly sensitive 
markers for vitamin B12 deficiency. Testing is widely available, 
but expensive, and some conditions (e.g. renal insufficiency) 
may falsely elevate serum homocysteine and methylmalonic 
acid levels.6 Because serum methylmalonic acid level is as 
sensitive as, but more specific than serum homocysteine level 
for vitamin B12 deficiency, it is the confirmatory test of choice. 
Measurement of cobalamin bound to transcobalamin would 
be a more physiologic measure of cobalamin status, but this 
assay is not yet routinely available and further research is 
needed about its clinical utility.4,6 Vitamin B12 levels may be 
found falsely lower in some coexisting conditions, such as 
multiple myeloma, pregnancy, folate deficiency and intake of 
oral contraceptives, while patients with liver or renal disease, 
or myeloproliferative disorders may have falsely normal levels.6
If patients are symptomatic there should be no question 
of treating the deficiency and a low vitamin B12 level should 
never be ignored. The medical profession has often relied on 
the presence of megaloblastic anemia as an indication to check 
vitamin B12 status. Changes in the blood film with macrocytosis 
and hypersegmented neutrophils are late manifestations of 
folate or vitamin B12 deficiency and should not be relied upon 
as an indication for testing of vitamin B12 levels. In addition, 
those with a very low vitamin B12 and a normal folate may not 
have a megaloblastic picture but will still be at risk of devel-
oping neuropsychiatric and cardiovascular sequelae. Serum 
concentrations of vitamin B12 may be low in the presence of 
normal tissue levels if there is concomitant folate deficiency, 
pregnancy, iron deficiency or in certain rare inherited disorders 
of vitamin B12 metabolism. Vitamin B12 deficiency should be 
suspected in all patients with unexplained anemia, unexplained 
neuropsychiatric symptoms, and/or gastrointestinal manifes-
tations with glossitis, anorexia, and diarrhea.4 Patients at risk 
of developing cobalamin deficiency include the elderly due 
to increased incidence of atrophic gastritis in this group, the 
vegetarians and the vegans, and patients with intestinal diseases. 
Other groups at risk include patients with autoimmune disor-
ders (Graves’ disease, thyroiditis, vitiligo), as well as patients 
receiving metformin, proton pump inhibitors, or histamine 
receptor antagonists for prolonged periods of time.12,17,19
Additional testing in order to determine the cause of 
vitamin B12 deficiency comprises antibodies to intrinsic factor 
which establish the diagnosis for pernicious anemia; however, 
only about 70% of patients with pernicious anemia have these 
antibodies. Other tests that are considered useful for detecting 
the cause of vitamin B12 deficiency include levels of pepsinogen 
and/or levels of plasma gastrin which are suggestive but not 
specific. For years, Shilling’s test, in which labeled vitamin 
B12 is administered orally alone (Shilling’s test I) or together 
with intrinsic factor (Shilling’s test II), has been deemed the 
gold standard test to investigate whether lack of the vitamin 
is caused by lack of intrinsic factor. Shilling’s test is, however, 
no longer available due to increasing difficulties in obtaining 
labeled vitamin B12 and intrinsic factor.4,8
t r E A t M E N t
There is no universal agreement on the recommendations 
for the treatment of vitamin B12 deficiency in those who do 
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not have pernicious anemia. Nevertheless, most physicians 
proceed with supplemental therapy in symptomatic patients.33 
However, apart from the symptomatic patient, a far more 
prevalent presentation is subclinical vitamin B12 deficiency in 
an asymptomatic individual with borderline serum B12 levels 
and elevated homocysteine or methylmalonic acid levels, or 
both.8,33 Such patients pose a therapeutic dilemma because 
there are no guidelines for their treatment. Some physicians 
elect to treat these patients aiming at having the metabolite 
markers normalized, while others prefer to withhold therapy 
and follow patients closely.
All patients with vitamin B12 <300-350 pg/ml should have 
their H. pylori status ascertained with serum antibodies (if they 
have not had previous treatment), breath test or stool antigen, 
and a discussion about the importance of a diet high in animal 
source foods and the usefulness of fortified cereals. Certain 
medications adversely affect vitamin B12 levels, including pro-
ton pump inhibitors, H2 antagonists, and metformin (Table 
1). Therefore patients using these medications will be unable 
to build up and maintain their stores of vitamin B12 and will 
remain deficient, even if diet improves and H. pylori is treated.
While oral treatment can be effective, its limitation is that 
with higher doses the ileal receptors for vitamin B12 intrinsic 
factor complex become saturated.33-35 The recommended 
dietary intake for adults is 2.4 μg/day (higher for pregnant or 
breastfeeding women) but only about 56% of a 1 μg oral dose 
will be absorbed. Absorption rates fall dramatically as dosage 
increases; in a >25 μg dose only 1% is absorbed. Even in people 
with normal absorption only 10 μg of 1000 μg will be absorbed; 
in those with H. pylori or G. lamblia, or those on proton pump 
inhibitors, metformin or H2 antagonists, the absorption rate 
will be even less.12.19
Oral doses of 1000–2000 μg/day, then weekly, then monthly 
have been proposed as effective as intramuscular injection 
in achieving a clinical response.4,8,33-35 However, the standard 
recommendation for patients with vitamin B12 deficiency due 
to pernicious anemia is 1 mg (1000 IU) of vitamin B12 given 
intramuscularly daily for 1 week, weekly for 1 month, then 
monthly indefinitely.8,36 Other protocols in pernicious anemia 
use 1 mg weekly for 1 month, and monthly thereafter. All 
patients should have their levels checked at 3-4 months and 
regularly afterwards.33
There appears to be evidence supporting the existence 
of an alternate system for the absorption of vitamin B12 that 
is independent of intrinsic factor or even an intact terminal 
ileum. Approximately 1% of a large dose of vitamin B12 (e.g. 
1000 μg) is absorbed by this second mechanism. This pathway 
is important in relation to oral replacement therapy. Once 
absorbed, vitamin B12 binds to transcobalamin II and is trans-
ported throughout the body. A clinical trial (project OB12) 
has been designed to compare the effectiveness of orally and 
intramuscularly administered vitamin B12 in the treatment of 
patients ≥65 years of age with vitamin B12 deficiency.37
Treatment with vitamin B12 is considered safe, even when 
very high vitamin serum levels are reached with doses 1000 
times the recommended daily allowance.1 Cobalamin has not 
been shown to be toxic or cause cancer, birth defects, or mu-
tations.1,8 However, one should be cognizant of the potential 
risk of hypokalemia and fluid overload early during treatment 
of patients with megaloblastic anemia due to increased eryth-
ropoiesis, cellular uptake of potassium, and increased blood 
volume. An entirely different situation exists when in the 
absence of cobalamin therapy, high plasma cobalamin levels 
(>800 pg/ml) are unexpectedly detected, whereby high plasma 
cobalamin denotes an alteration in cobalamin metabolism with 
either increased synthesis or decreased clearance of cobalamin-
binding proteins (transcobalamin and/or haptocorin) or release 
of cobalamin from body stores. An association of unexpected 
high cobalamin levels has been reported with hematologic 
malignancies, liver disease and cancer, autoimmune disease, 
renal disease and infections.38
There has been a great deal of interest in the link between 
elevated levels of homocysteine, a direct consequence of vi-
tamin B12 deficiency, and cardiovascular disease. No studies 
have directly evaluated the cardiovascular effects of correcting 
vitamin B12 deficiency in patients with known cardiovascular 
disease, although numerous studies have failed to demonstrate 
that correction of hyperhomocysteinemia itself reduces car-
diovascular mortality or cardiovascular complications.12,39-45 
The routine use of vitamin B12 to lower levels of serum ho-
mocysteine in patients at high risk of cardiovascular events is 
not recommended.12
c O N c l U s I O N
Vitamin B12 deficiency is a common, albeit frequently 
missed, problem in adult patients, particularly in the elderly. 
Neuropsychiatric manifestations can be the presenting and only 
sign of cobalamin deficiency even in the absence of hematologic 
abnormalities. The deficiency can occur despite “normal” 
serum cobalamin levels; thus, measuring homocysteine and 
MMA in patients having vitamin B12 levels <350 pg/ml can 
decrease false-negative findings. Early detection and treatment 
are important to prevent structural and irreversible damage. 
Oral high-dose treatment has been proposed as efficacious as 
parenteral treatment but further confirmatory data are needed. 
Devising a strategy to select patients with subtle or subclinical 
vitamin B12 deficiency who would benefit from supplemental 
therapy remains an important issue for future research.
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